Syndax Pharmaceuticals is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.85 – an increase of 8.84% over the previous week. Syndax Pharmaceuticals employs 270 staff and has a trailing 12-month revenue of around $43.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $9.85 |
|---|---|
| 52-week range | $8.58 - $25.07 |
| 50-day moving average | $12.21 |
| 200-day moving average | $15.85 |
| Wall St. target price | $34.36 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.85 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.81 from 2025-05-22
| 1 week (2025-05-16) | 19.45% |
|---|---|
| 1 month (2025-04-24) | -18.72% |
| 3 months (2025-02-24) | -31.01% |
| 6 months (2024-11-22) | -32.82% |
| 1 year (2024-05-24) | -46.70% |
|---|---|
| 2 years (2023-05-24) | -49.46% |
| 3 years (2022-05-24) | 14.17 |
| 5 years (2020-05-22) | 16 |
| Revenue TTM | $43.7 million |
|---|---|
| Gross profit TTM | $-199,636,000 |
| Return on assets TTM | -36.29% |
| Return on equity TTM | -93.7% |
| Profit margin | 0% |
| Book value | $2.50 |
| Market Capitalization | $778.7 million |
TTM: trailing 12 months
We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $8.58 up to $25.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 0.821. This would suggest that Syndax Pharmaceuticals's shares are less volatile than average (for this exchange).
Syndax Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
A deep dive into the highlights and limitations of Frec.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.